1H-19F Gastrointestinal MRI in Health and IBS

Condition(s) targeted: Irritable Bowel Syndrome

Intervention: 19F capsule (Device); sterculia (Dietary Supplement)

Phase: N/A

Status: Suspended

Sponsored by: University of Zurich

Official(s) and/or principal investigator(s):
Werner Schwizer, Prof. MD, Principal Investigator, Affiliation: University Hospital Zurich, Gastroenterology & Hepatology

The aim of this project is to demonstrate and validate the ionizing radiation free and non invasive assessment of small intestinal anatomy, content and function in healthy and disease by a newly developed combined proton (1H) and fluorine (19F) magnetic resonance imaging (MRI) framework. Meal induced and pathology related alterations in small intestinal motor activity, gas distribution and anatomy of healthy volunteers and patients with irritable bowel syndrome (IBS) will be analyzed with this non invasive MRI approach. The multinuclear imaging framework consists of a 1H and 19F capable clinical 3T MRI system with standard 1H abdominal surface coils, a dual-channel transmit-receive abdominal 19F surface coil, fluorine labelled impermeable and biocompatible capsules for oral administration (19F capsule) and a 19F projection imaging sequence allowing for the non-invasive detection of the gastrointestinal positions of single and multiple ingested capsules in real time. Dedicated post-processing algorithms are applied to extract parameters of intestinal motor activity from the detected intraluminal capsule movements. The proposed unique imaging modality allows for the concurrent, non invasive and repeated analysis of important physiologic parameters of intestinal function together with detailed anatomical information and thus presents an ideal tool for the evaluation of the analyzed parameters as potential biomarkers in IBS.

- Trial with medical device

Official title: Small Intestinal Transit and Motor Function in Health and IBS Patients Studied by Combined 1H and 19F Magnetic Resonance Imaging

Study design: Observational Model: Case Control, Time Perspective: Prospective

Primary outcome: Small intestinal transit time in minutes

Secondary outcome:

Small intestinal length and intestinal course

Small intestinal motor activity index

Small intestinal transport velocity

Local intestinal residence times

Volume and distribution of intestinal gas

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion criteria:

- Healthy volunteers and IBS patients must fill out the validated Birmingham IBS

Symptom Questionnaire

- Healthy volunteers must be symptom free of any abdominal complaints.

- IBS patients are defined based on clinical symptoms as described in the Rome III

criteria for irritable bowel syndrome:

- Symptoms of recurrent abdominal pain or discomfort and a marked change in bowel

habit for at least six months, with symptoms experienced on at least three days of at least three months. Two or more of the following must apply:

- Pain is relieved by bowel movement

- Onset of pain is related to a change in frequency of stool

- Onset of pain is related to a change in the appearance of stool

- Written informed consent

Exclusion criteria:

- Age under 18 or above 65

- Pathologic underweight or overweight (BMI <18 or >30kg/m2)

- Previous history of gastrointestinal disease or surgery (excludes appendectomy,

cholecystectomy, hernia repair and anorectal disorders)

- Previous cardiorespiratory (excludes arterial hypertension), hematologic, renal,

atopic, alimentary or psychiatric disease, diabetes, drug or alcohol abuse, psychiatric disease

- Patient unable to stop medication that alters gut function for 72 hours prior to the

study, including anticholinergics, prokinetics, proton-pump inhibitors, non-steroidal antiinflammatory drugs

- Presence of metallic implants, devices or metallic foreign bodies

- Pregnancy and lactation (female patients of child bearing age will receive a

pregnancy test prior to study)

- Female volunteers without adequate contraception for the duration of the study

Involvement in any other clinical trial during the course of this trial, nor within a period of 30 days prior to its beginning or 30 days after its completion

- Allergy against silicone

- Claustrophobia

University Hospital Zurich, Gastroenterology, Zurich, Switzerland

Starting date: July 2011
Last updated: April 8, 2015